Marked as
Last updated - November 21, 2025
User Score
Trust Score
Brand Score
Humanigen is a U.S. biopharma firm developing immune-targeting therapies like lenzilumab. It maintains industry partnerships but has faced reputational challenges, including SEC allegations involving former executives and shareholder litigation tied to regulatory disclosures. The company continues development while seeking to rebuild public trust.
Chairman and CEO
High Risk
Based on the available data, we advise consumers to avoid this Company altogether.
This advisory is based on an aggregate risk score derived from OSINT, Adverse Media, Reviews, and Risk Factors identified in our research.
You are likely to be at great risk by engaging in any sort of consumer-related activity with this entity.
Based on the available data, we recommend that employees exercise extreme caution or reconsider association with this Company.
This advisory stems from an aggregate risk score compiled from OSINT, Adverse Media, Reviews, and Risk Factors uncovered in our analysis.
You are likely to face significant risks by pursuing or maintaining employment with this entity.
Medium Risk
Based on the available data, we recommend investors and bankers proceed with caution regarding this Company.
This advisory is informed by a medium-risk score based on OSINT, Adverse Media, Reviews, and Risk Factors identified through our investigation.
Financial involvement with this entity may carry moderate risks to your interests.
Safe to Onboard
Enhanced Due Diligence required
Do Not Onboard
Monitor adverse media every 6 months
File SAR (Suspicious Activity Report) is warranted
Escalation to compliance committee
None
Name
Sector
Industry
Category
Focus
Product
CEO
CFO
Status
Website
Location
State
Country
Address
Exchange
Filing
Risk
Litigation
Enforcement
Governance
Reputation
Humanigen is a U.S.-based biopharmaceutical company focused on developing therapies targeting immune system pathways.
The company’s primary product candidate is lenzilumab, developed for immune-driven and inflammatory conditions.
Public SEC filings reference regulatory enforcement actions involving former executives.
Shareholder litigation has been filed related to disclosures and regulatory outcomes.
The company has experienced adverse media coverage tied to regulatory allegations and financial setbacks.
Humanigen continues to operate as a biopharmaceutical development company focused on immunology-based therapies.
Regulatory and Compliance Screening
Litigation and Legal Proceedings
Reputational and Adverse Media Risks
Geographic and Jurisdictional Risk
What you see here scratches the surface
We offer reward for actionable intel
The article details alleged insider trading at Humanigen via manipulated 10b5‑1 plans and FDA info.
First Detected
Sentiment Analysis
Reach
POV
Risk Factor
Type
Traffic Source
SERP
Share of Voice
Primary Keyword
Edelson law alleges Humanigen misled investors on lenzilumab efficacy and FDA risks.
DOJ charges Humanigen exec for insider trading using FDA info and 10b5‑1 plan manipulation.
Other Red-Flags and Adverse News
Based on user engagement on this review profile, ProConsumer will decide to publish its Risk Audit report for public if a threshold engagement, traffic and user input is achieved.
Known Assets: [Real estate, investments, companies]
Suspicious Transactions
Liabilities: [Bankruptcies, defaults, debts]
Wealth Sources: [Legitimate / Unclear / High-risk]
Bank Relationships
Ultimate Beneficial Owner(s) (UBOs)
Shareholding structure
Associated entities & subsidiaries
Offshore / shell company links
Trusts / Nominee arrangements
Business Model Assessment
All comments are user-generated content and may not be verified. They represent the personal opinions of the public and should not be relied upon. These comments do not influence or determine our overall rating.
0
Highly experienced
Well-recognized name
Faced allegations of scamming others
Allegedly sold fake silver
Sued multiple times
Unregulated industry
Alarming number of complaints online
Δ
T & M Contracts Limited (SC089502) is a long-established Scottish construction and haulage company incorporated in 1984 and formerly based in Glenrothes, Fife. It entered compulsory liquidation on 21 July 2023 and is no longer trading.
Alexvit Group is a Belarus-based logistics and trading firm owned by Sergei Borisyuk, with reported affiliations to Viktar Sheiman. Investigations highlight alleged involvement in exporting restricted microchips to Russia, along with opaque ownership structures and elevated reputational and sanctions-related risks. The company’s activities raise ongoing scrutiny from independent monitoring sources.
Be Saha Hospitality Group, founded by Amar Harrag, is a San Diego–based company operating bars and restaurants including Wormwood, Botanica, Hidden Craft, and Tahona, and managing food and beverage operations for The Guild Hotel. The group is under investigation by the San Diego District Attorney for alleged unpaid wages, bounced checks, and withheld gratuities from employees.
LPL Financial LLC is one of the largest independent broker-dealer and investment advisory firms in the United States, providing brokerage, advisory, and compliance support services to financial professionals. The firm serves independent advisors, financial institutions, and wealth-management practices through a platform of investment products, technology, and operational support.
JR Wealth Management, founded by Jonathane Michael Ricci in Toronto, presents itself as a firm offering wealth advisory and portfolio services for high-net-worth clients. However, Ricci’s indefinite suspension by the Law Society of Ontario for professional misconduct.
Bremer Bank is a regional US bank headquartered in Minnesota, with a focus on commercial and community banking services. It is tied to the Otto Bremer Trust and employee-shareholder ownership structure. The bank faces legal scrutiny over governance practices and class-action lawsuits claiming unfair overdraft fees and withheld voting rights.
Ushare, associated with SPM Srl, markets DT‑Coin and related tokens through an MLM-style structure. The company has faced widespread criticism for relying heavily on recruitment over product value, lacking transparent financial data, and exhibiting characteristics commonly linked to pyramid schemes, raising significant reputational and consumer-risk concerns.
Falinas.com has gained a negative reputation for luring shoppers with extremely low-priced product offers that ultimately lead to hidden subscription traps. Many consumers report being charged recurring fees despite believing they made a one-time purchase. The platform’s unclear terms and misleading checkout process have triggered multiple warnings from consumer protection authorities across Europe.
FXNovus is surrounded by troubling reports of withdrawal delays, pressure tactics, and regulatory limitations. Traders considering this broker should proceed with extreme caution and prioritize their financial safety.
© 2025 Proconsumer. All rights reserved.